Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients.
- EligibilityCriteria: Inclusion Criteria:  Age ≥ 18 years, gender not specified. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) confirmed by histopathological examination. Patients should test positive for plasma cfDNA before treatment (defined as positive for point mutations, CNV, IgH-related fusion, or IG clonal rearrangement) and achieve complete metabolic remission after 6 cycles of R-CHOP chemotherapy (evaluated by Lugano response assessment criteria). Patients for whom the researcher predicts a life expectancy of >6 months. Signed informed consent form.  Exclusion Criteria:  Patients who have undergone autologous stem cell transplantation. Patients with a history of other malignant tumors, except for basal cell carcinoma of the skin or in situ cervical cancer. Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, and other such conditions; Primary central nervous system lymphoma. Patients with mental illness or others known or suspected to be unable to fully comply with the study protocol. Pregnant or lactating women. HbsAg-positive patients who need to undergo HBV-DNA testing and can only be included if they seroconvert. Additionally, if the HbsAg test is negative but the HBcAb test is positive (regardless of HbsAb status), HBV-DNA testing is also required. If the result is positive, inclusion is possible only after seroconversion. HIV-infected individuals. Other concurrent and uncontrolled diseases that researchers believe may affect the medical condition of patients participating in the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult